Åslaug Helland
Oslo University Hospital · Radium Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Åslaug Helland as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:20 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04817956 · Improving Public Cancer Care by Implementing Precision Medicine in NorwayOslo University Hospital · recruiting · Cancer Metastatic · principal investigator
- Ph2NCT04392505 · Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker StudyOslo University Hospital · active not recruiting · Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage III · principal investigator
- Ph2NCT04300244 · Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant MesotheliomaÅslaug Helland · active not recruiting · Cancer, Cancer, Lung, Cancer of Lung · principal investigator
- Ph2NCT03644823 · Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLCOslo University Hospital · terminated · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT02714530 · Thoracal Radiotherapy and TarcevaOslo University Hospital · terminated · Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:20 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.Lancet Oncol · 2017767 citationsRCR 23.4
- 264 citationsRCR 8.7
- Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.J Thorac Oncol · 2021162 citationsRCR 8.0
- Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.J Thorac Oncol · 2018136 citationsRCR 3.6
- Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).Lung Cancer · 202062 citationsRCR 2.4
- The immune microenvironment in non-small cell lung cancer is predictive of prognosis after surgery.Mol Oncol · 201960 citationsRCR 1.9
- Comparison of driving simulator performance with real driving after alcohol intake: a randomised, single blind, placebo-controlled, cross-over trial.Accid Anal Prev · 201349 citationsRCR 2.7
- Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.Dis Markers · 201749 citationsRCR 1.8
- 44 citationsRCR 1.7
- 40 citationsRCR 1.2